Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02737202 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
A Phase 2 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02737202 is a Phase 2 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 28 participants.
The verdict
NCT02737202, a Phase 2 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is being done to determine if there is a potential benefit of saracatinib in LAM subjects. Based on the information of this trial, additional clinical development trials will be needed. The study will also test the tolerability of 125 mg of saracatinib given once daily over a 9 month period.
Interventions
- DRUG saracatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02737202
The ClinicalTrials.gov registry entry for NCT02737202 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which saracatinib is the first listed.
NCT02737202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02737202 about?
NCT02737202 is a clinical study titled "Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis". This study is being done to determine if there is a potential benefit of saracatinib in LAM subjects. Based on the information of this trial, additional clinical development trials will be needed. The study will also test the tolerability of 125 mg of saracatinib given once daily over a 9 month peri...
What is the current status of trial NCT02737202?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2016-04. Estimated completion is 2019-07-30.
What interventions are being tested in trial NCT02737202?
The interventions under investigation include: saracatinib (DRUG).
Who is sponsoring clinical trial NCT02737202?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.